Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dose-Response Relationship: Overview

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...

Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect

Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect

A drug’s dosage and pharmacokinetic properties determine how quickly it acts, how intense its effects are, and how long it lasts. Higher doses increase drug concentration at receptor sites, producing a hyperbolic curve when pharmacologic response is plotted against drug dose. Converting this scale to a log-linear format results in a sigmoidal curve, better representing dose–response relationships.For drugs following a one-compartment model, the pharmacologic response is directly proportional to...

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...

Pharmacokinetic–Pharmacodynamic Relationship: Intensity of Dose-Effect Relationship

Pharmacokinetic–Pharmacodynamic Relationship: Intensity of Dose-Effect Relationship

Pharmacodynamics explores the relationship between drug concentration and its effect. In a quantal response drug, the duration of action better correlates with drug concentration, while for graded effect drugs, the intensity of response is more relevant. This intensity depends on the dose, drug removal rate, and the region of the concentration–response curve.The concentration–response curve can be divided into three regions. Region 3 (80–100% maximum response) demonstrates that even as drug...

Pharmacokinetic–Pharmacodynamic Relationship: Problems

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cychlorphine (<i>N</i>-Propionitrile Chlorphine): An Emerging Benzimidazolone Synthetic Opioid and Its Implications for Overdose Recognition and Management.

Journal of pain research·2026

Same author

Psychedelics and Ibogaine "Pain Medications" at the Pharmacy Counter: Implications for Pharmacy Practice.

Journal of pain research·2026

Same author

On the Coexistence of Monitoring and Dampening of Pain Perception During the Fight-or-Flight Response.

Cureus·2026

Same author

Combination of the BK-Channel Antagonist ENA-001 and Naloxone Is More Effective Than Either Agent Alone in Reversing Fentanyl-Induced Respiratory Suppression in Rats.

Cureus·2026

Same author

A Pain Memory "Trace": Cumulative Pain Perception and Damping During Fight-or-Flight Response Modeled with a Lotka-Volterra-Style Coupled Feedback Control Loop System.

Journal of pain research·2026

Same author

Defining, Evaluating, and Managing Postoperative Respiratory Depression: An e-Delphi Study.

Cureus·2026

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

On deriving the dose-effect relation of an unknown second component: an example using buprenorphine preclinical data.

Ronald J Tallarida¹, Alan Cowan, Robert B Raffa

¹Department of Pharmacology, Temple University School of Medicine and Center for Substance Abuse Research, 3420 N. Broad Street, Philadelphia, PA 19140, United States. ronald.tallarida@temple.edu

Drug and Alcohol Dependence

|January 12, 2010

Summary

Buprenorphine shows a biphasic dose-response, with pain relief increasing then decreasing at higher doses. This study quantifies this effect, revealing insights into buprenorphine

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Related Experiment Videos

Last Updated: Jun 17, 2026

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

Diagonal Method to Measure Synergy Among Any Number of Drugs

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Area of Science:

Pharmacology
Neuroscience
Pain Research

Background:

Buprenorphine exhibits hormesis, a biphasic dose-response relationship, where antinociceptive effects increase and then decrease with dose.
This phenomenon is observed in preclinical models, including tail-flick tests in mice and rats.
The precise mechanism for the dose-related decline in antinociception remains unclear, though nociceptin/orphanin-FQ is a potential factor.

Purpose of the Study:

To investigate and quantify the dose-effect relation of the decreasing component of buprenorphine's biphasic antinociceptive effect.
To apply a novel calculation technique based on dose equivalence to analyze tail-flick data.
To explore potential insights into the dual therapeutic applications of buprenorphine.

Main Methods:

Utilized tail-flick tests in mice and rats to assess antinociceptive effects of buprenorphine at various doses.
Employed a calculation method derived from isobolographic analysis principles to determine the dose-effect relation of the decreasing component.
Analyzed derived dose-effect curves for similarities and differences between species.

Main Results:

A decreasing component of antinociceptive effect was evident in both mouse and rat tail-flick tests.
The novel calculation technique successfully derived dose-effect curves for this second component.
Despite differences in efficacy, the derived curves showed notable similarity between mice and rats.

Conclusions:

The study successfully quantified the dose-effect relation of the decreasing component of buprenorphine's antinociception.
The observed similarity in derived curves suggests a conserved underlying mechanism across species.
This quantitative approach provides valuable insights into buprenorphine's complex pharmacology and its dual use as an analgesic and addiction medication.